Pharmaceutical and biotech company

Sanaria Inc.

Develop

Endemic countries

U.S. states

Products and programs

About

What they do

Sanaria grows, purifies, and cryopreserves weakened malaria parasites to make whole-parasite (PfSPZ) vaccines designed to provide strong, long-lasting protection against malaria for people in endemic areas and travelers.¹ Its U.S. R&D and vaccine manufacturing are based in Rockville, Maryland.¹ Its work is in the development stage: its flagship third-generation vaccine, PfSPZ-LARC2 Vaccine, a late-arresting, replication-competent, genetically attenuated vaccine, has been assessed in five clinical trials over the past year and is now in Phase 2 trials in Burkina Faso and Mali testing protection against naturally transmitted malaria.^2,3,1

In the United States

Rockville, MD¹Headquarters · Research and development · Manufacturing

Products and programs

In the field and in development

PfSPZ-LARC2 Vaccine^2,3,1

PfSPZ Vaccine¹

PfSPZ-CVac¹

PfSPZ Challenge¹

Where they work

Partnerships in 6 endemic countries

Clinical trialsResearchPrograms and delivery

Burkina Faso

Africa

Groupe de Recherche Action en Santé (GRAS) / Unité de Recherche Clinique de Sabou / Unité de Recherche Clinique de Banfora · clinical trial sites for PfSPZ-LARC2 Vaccine, including Phase 1 age de-escalation and Phase 2 field trials^4,3,1

Gabon

Africa

Centre de Recherches Médicales de Lambaréné · clinical trial sites for PfSPZ Vaccine to assess vaccine-induced protection in children and PfSPZ Challenge to assess naturally acquired and innate immunity¹

Indonesia

Asia-Pacific

Faculty of Medicine, Universitas Indonesia; Oxford University Clinical Research Unit (OUCRU) Indonesia; Army of the Republic of Indonesia/Gatot Soebroto Army Hospital; Ministry of Health; and National Research and Innovation Agency (BRIN) · collaborators in the Phase 2 trial of PfSPZ Vaccine and PfSPZ-CVac in malaria-naïve Indonesian soldiers deployed to Papua; Sanaria provided the investigational vaccines¹

Kenya

Africa

Kenya Medical Research Institute (Kilifi, Kisumu, Nairobi) · studies using PfSPZ Challenge to assess naturally acquired immunity and vaccine-induced protection in infants¹

Mali

Africa

University of Sciences, Techniques and Technologies of Bamako, Malaria Research and Training Center · clinical trials of PfSPZ Vaccine and Phase 2 clinical trial of PfSPZ-LARC2 Vaccine^5,1

Tanzania

Africa

Ifakara Health Institute · clinical trial site for PfSPZ Vaccine and PfSPZ Challenge to assess vaccine-induced protection in adults and children¹

U.S. partners

Who they work with in the United States

National Institute of Allergy and Infectious Diseases / NIH¹
Bethesda/Rockville, MD · Funder · funder and collaborator
Gates Foundation¹
Seattle, WA · Funder · funder
In the atlas
University of Washington¹
Seattle, WA
In the atlas
Seattle Children's Research Institute^6,1
Seattle, WA · Funder · funder and collaborator
In the atlas
Walter Reed Army Institute of Research¹
Silver Spring, MD
In the atlas
University of Maryland — Center for Vaccine Development and Global Health¹
Baltimore, MD
In the atlas
University of Maryland — Institute for Genome Sciences¹
Baltimore, MD
University of Maryland — Institute for Bioscience and Biotechnology Research¹
Rockville, MD
Fred Hutchinson Cancer Center¹
Seattle, WA
In the atlas
Johns Hopkins University — Engineering/Robotics¹
Baltimore, MD
National Center for Advancing Translational Sciences, NIH¹
Bethesda, MD · Funder · funder
Oregon Health & Science University¹
Portland, OR
In the atlas
UCLA¹
Los Angeles, CA
MIT¹
Cambridge, MA
In the atlas

Sources

Sanaria Inc.

What they do

In the field and in development

Partnerships in 6 endemic countries

Who they work with in the United States

Where this comes from